Your browser doesn't support javascript.
loading
IL-1ß+ macrophages fuel pathogenic inflammation in pancreatic cancer.
Caronni, Nicoletta; La Terza, Federica; Vittoria, Francesco M; Barbiera, Giulia; Mezzanzanica, Luca; Cuzzola, Vincenzo; Barresi, Simona; Pellegatta, Marta; Canevazzi, Paolo; Dunsmore, Garett; Leonardi, Carlo; Montaldo, Elisa; Lusito, Eleonora; Dugnani, Erica; Citro, Antonio; Ng, Melissa S F; Schiavo Lena, Marco; Drago, Denise; Andolfo, Annapaola; Brugiapaglia, Silvia; Scagliotti, Alessandro; Mortellaro, Alessandra; Corbo, Vincenzo; Liu, Zhaoyuan; Mondino, Anna; Dellabona, Paolo; Piemonti, Lorenzo; Taveggia, Carla; Doglioni, Claudio; Cappello, Paola; Novelli, Francesco; Iannacone, Matteo; Ng, Lai Guan; Ginhoux, Florent; Crippa, Stefano; Falconi, Massimo; Bonini, Chiara; Naldini, Luigi; Genua, Marco; Ostuni, Renato.
Afiliação
  • Caronni N; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy. caronni.nicoletta@hsr.it.
  • La Terza F; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Vittoria FM; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Barbiera G; Vita-Salute San Raffaele University, Milan, Italy.
  • Mezzanzanica L; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cuzzola V; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Barresi S; Vita-Salute San Raffaele University, Milan, Italy.
  • Pellegatta M; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Canevazzi P; Vita-Salute San Raffaele University, Milan, Italy.
  • Dunsmore G; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Leonardi C; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Montaldo E; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Lusito E; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
  • Dugnani E; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Citro A; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ng MSF; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Schiavo Lena M; Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Drago D; Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Andolfo A; Singapore Immunology Network (SIgN), A*STAR, Singapore, Singapore.
  • Brugiapaglia S; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Scagliotti A; Center for Omics Sciences (COSR), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Mortellaro A; Center for Omics Sciences (COSR), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Corbo V; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • Liu Z; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • Mondino A; San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Dellabona P; University of Verona, Verona, Italy.
  • Piemonti L; Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Taveggia C; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Doglioni C; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Cappello P; Vita-Salute San Raffaele University, Milan, Italy.
  • Novelli F; Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Iannacone M; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ng LG; Vita-Salute San Raffaele University, Milan, Italy.
  • Ginhoux F; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Crippa S; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • Falconi M; Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
  • Bonini C; Vita-Salute San Raffaele University, Milan, Italy.
  • Naldini L; IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Genua M; Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ostuni R; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.
Nature ; 623(7986): 415-422, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37914939
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with high resistance to therapies1. Inflammatory and immunomodulatory signals co-exist in the pancreatic tumour microenvironment, leading to dysregulated repair and cytotoxic responses. Tumour-associated macrophages (TAMs) have key roles in PDAC2, but their diversity has prevented therapeutic exploitation. Here we combined single-cell and spatial genomics with functional experiments to unravel macrophage functions in pancreatic cancer. We uncovered an inflammatory loop between tumour cells and interleukin-1ß (IL-1ß)-expressing TAMs, a subset of macrophages elicited by a local synergy between prostaglandin E2 (PGE2) and tumour necrosis factor (TNF). Physical proximity with IL-1ß+ TAMs was associated with inflammatory reprogramming and acquisition of pathogenic properties by a subset of PDAC cells. This occurrence was an early event in pancreatic tumorigenesis and led to persistent transcriptional changes associated with disease progression and poor outcomes for patients. Blocking PGE2 or IL-1ß activity elicited TAM reprogramming and antagonized tumour cell-intrinsic and -extrinsic inflammation, leading to PDAC control in vivo. Targeting the PGE2-IL-1ß axis may enable preventive or therapeutic strategies for reprogramming of immune dynamics in pancreatic cancer.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Interleucina-1beta / Macrófagos Associados a Tumor / Inflamação Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Interleucina-1beta / Macrófagos Associados a Tumor / Inflamação Limite: Humans Idioma: En Revista: Nature Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália